Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer

[1]  S. Wallet,et al.  Targeting tumor tolerance: A new hope for pancreatic cancer therapy? , 2016, Pharmacology & therapeutics.

[2]  H. Lee,et al.  Systemic Chemotherapy in Advanced Pancreatic Cancer , 2016, Gut and liver.

[3]  C. Figdor,et al.  Dendritic Cell–Based Immunotherapy: State of the Art and Beyond , 2016, Clinical Cancer Research.

[4]  T. Wagner,et al.  A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor–dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2 , 2016, Cancer Immunology, Immunotherapy.

[5]  Yan-Shen Shan,et al.  Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial , 2016, The Lancet.

[6]  Y. Liu,et al.  Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer , 2016, Journal of Hematology & Oncology.

[7]  L. Butterfield.  Lessons learned from cancer vaccine trials and target antigen choice , 2016, Cancer Immunology, Immunotherapy.

[8]  C. Gomes,et al.  Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. , 2016, Translational research : the journal of laboratory and clinical medicine.

[9]  L. Butterfield,et al.  Prospective Clinical Testing of Regulatory Dendritic Cells in Organ Transplantation , 2016, Front. Immunol..

[10]  C. Figdor,et al.  Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination , 2016, Oncoimmunology.

[11]  Y. Kim,et al.  A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma , 2015, British Journal of Cancer.

[12]  Yue Zhang,et al.  Immune Therapy in Pancreatic Cancer: Now and the Future? , 2015, Reviews on recent clinical trials.

[13]  J. Lacy,et al.  Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity , 2015, Experimental Hematology & Oncology.

[14]  E. Parati,et al.  Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients , 2015, Stem cells translational medicine.

[15]  Weijing Sun,et al.  Advances in the management of gastrointestinal cancers—an upcoming role of immune checkpoint blockade , 2015, Journal of Hematology & Oncology.

[16]  Maarten A. Bijl,et al.  DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift. , 2015, Vaccine.

[17]  Delong Liu,et al.  Novel agents for advanced pancreatic cancer , 2015, Oncotarget.

[18]  Y. Li,et al.  Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate Cancer. , 2015, Biological & pharmaceutical bulletin.

[19]  M. Babjuk,et al.  Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer , 2015, Oncotarget.

[20]  A. Seicean,et al.  New targeted therapies in pancreatic cancer. , 2015, World journal of gastroenterology.

[21]  S. Gazzaniga,et al.  Dendritic Cell-Based Vaccination in Cancer: Therapeutic Implications Emerging from Murine Models , 2015, Front. Immunol..

[22]  E. Mardis,et al.  A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells , 2015, Science.

[23]  Weijing Sun,et al.  Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future , 2015, Journal of Hematology & Oncology.

[24]  E. Jaffee,et al.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[26]  J. Wolchok,et al.  On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation , 2015, Science Translational Medicine.

[27]  J. Prieto,et al.  Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection , 2015, Molecular therapy. Methods & clinical development.

[28]  T. Sakurai,et al.  Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer , 2015, Cancer science.

[29]  S. Bavari,et al.  Vaccine adjuvant uses of poly-IC and derivatives , 2015, Expert review of vaccines.

[30]  M. Kundranda,et al.  Promising new therapies in advanced pancreatic adenocarcinomas. , 2014, Future oncology.

[31]  G. Tortora,et al.  Pancreatic cancer: systemic combination therapies for a heterogeneous disease. , 2014, Current pharmaceutical design.

[32]  G. Kvalheim,et al.  New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia , 2014, Cancer Immunology, Immunotherapy.

[33]  H. Kume,et al.  A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma , 2014, Journal of Immunotherapy for Cancer.

[34]  L. Mendoza.  Dendritic cell vaccines against non-small cell lung cancer -  an emerging therapeutic alternative. , 2014, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

[35]  M. Dhodapkar,et al.  Recent advances and new opportunities for targeting human dendritic cells in situ , 2014, Oncoimmunology.

[36]  L. Zitvogel,et al.  Dendritic Cell–Derived Exosomes as Immunotherapies in the Fight against Cancer , 2014, The Journal of Immunology.

[37]  Z. Berneman,et al.  Clinical use of dendritic cells for cancer therapy. , 2014, The Lancet. Oncology.

[38]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[39]  L. Butterfield.  Dendritic Cells in Cancer Immunotherapy Clinical Trials: Are We Making Progress? , 2013, Front. Immunol..

[40]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[41]  R. Vonderheide,et al.  Inflammatory networks and immune surveillance of pancreatic carcinoma. , 2013, Current opinion in immunology.

[42]  M. Lotze,et al.  The Receptor for Advanced Glycation End Products Promotes Pancreatic Carcinogenesis and Accumulation of Myeloid-Derived Suppressor Cells , 2013, The Journal of Immunology.

[43]  R. Steinman.  Decisions about dendritic cells: past, present, and future. , 2012, Annual review of immunology.

[44]  Karolina Palucka,et al.  Cancer immunotherapy via dendritic cells , 2012, Nature Reviews Cancer.

[45]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[46]  J. Engh,et al.  Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  S. Nelson,et al.  Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy , 2010, Clinical Cancer Research.

[48]  Ira Mellman,et al.  Designing vaccines based on biology of human dendritic cell subsets. , 2010, Immunity.

[49]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[50]  A. Al-Khami,et al.  Recovery from Cyclophosphamide-Induced Lymphopenia Results in Expansion of Immature Dendritic Cells Which Can Mediate Enhanced Prime-Boost Vaccination Antitumor Responses In Vivo When Stimulated with the TLR3 Agonist Poly(I:C)1 , 2009, The Journal of Immunology.

[51]  K. Gourgoulianis,et al.  Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals. , 2008, Clinical immunology.

[52]  D. Mavroudis,et al.  Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  C. Jaffe.  Measures of response: RECIST, WHO, and new alternatives. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Mark J. Ratain,et al.  Measuring response in a post-RECIST world: from black and white to shades of grey , 2006, Nature Reviews Cancer.

[56]  C. Köhne,et al.  Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells , 2006, Cancer Immunology, Immunotherapy.

[57]  J. Becker,et al.  Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. , 2005, Vaccine.

[58]  Zui Tan,et al.  Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2. , 2004, World journal of gastroenterology.

[59]  L. Butterfield,et al.  Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro. , 2003, Cancer research.

[60]  P. Dalerba,et al.  The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. , 2003, Cancer research.

[61]  Javier Hernández,et al.  Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[62]  H. Kaufman,et al.  CEA-based vaccines , 2002, Expert review of vaccines.

[63]  F. Lemonnier,et al.  HER-2/neu and hTERT Cryptic Epitopes as Novel Targets for Broad Spectrum Tumor Immunotherapy1 , 2002, The Journal of Immunology.

[64]  A. Masamune,et al.  Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors , 2001, Cancer.

[65]  J. Shay,et al.  Telomerase activity is detected in pancreatic cancer but not in benign tumors. , 1997, Cancer research.

[66]  J. Ozols,et al.  Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[67]  M. Iadarola,et al.  A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. , 1975, The Journal of infectious diseases.

[68]  N. Zamcheck,et al.  Carcinoembryonic antigen (CEA) in the diagnosis of pancreatic cancer , 1973, Cancer.

[69]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[70]  M. Salem.  The use of dendritic cells for peptide-based vaccination in cancer immunotherapy. , 2014, Methods in molecular biology.

[71]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[72]  T. Schumacher,et al.  Testing for HLA/peptide tetramer-binding to the T cell receptor complex on human T lymphocytes. , 2012, Results in immunology.

[73]  K. Behrns.  FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer , 2012 .

[74]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.